Combination Treatment Appears Beneficial for Chronic Migraine
Data analysis revealed that CGRP mAbs were discontinued more frequently than onabotulinumtoxinA (23% vs 3%).
Migraine
Atogepant Under Review for Episodic Migraine Prevention
Atogepant is an investigational orally administered calcitonin gene-related peptide (CGRP) receptor antagonist.
MPR Weekly Dose Podcast 70
This week we have news of an indication for the cancer treatment, Keytruda, being withdrawn; Janssen’s single dose vaccine gains Emergency Use Authorization; There’s findings on the effectiveness of ivermectin as a therapy for mild COVID-19; And devices to treat migraine and prevention of sub-concussive head impacts are authorized for marketing.
MPR Weekly Dose Podcast 69
An FDA warning to pharma company regarding their promo material; Entresto’s approval is expanded; There’s approvals in homozygous familial hypercholesterolemia and chronic inflammatory demyelinating polyneuropathy; And a migraine device is OK’d for teens.
FDA Clears Vagus Nerve Stimulation Device for Adolescent Migraine
Findings from an adolescent study showed that 46.8% of treated attacks were successfully resolved without the use of any acute rescue medication.
Headache May Be an Early, Isolated Feature of COVID-19
Headache may be an early symptom of COVID-19, and identifying patients with characteristic features may help provide early isolation and treatment.
Nerivio Device Cleared for Migraine in Adolescents
The approval was based on data from an open-label, single-arm study that evaluated the efficacy and safety of Nerivio in patients aged 12 to 17 years with migraine.
Novel Intranasal DHE Under Review for Migraine
INP104 uses proprietary technology to deliver a lower dose (1.45mg) of dihydroergotamine mesylate (DHE) to the upper nasal space.
NDA Submitted for Novel Intranasal DHE for Migraine
INP104 uses proprietary technology to deliver a lower dose (1.45mg) of dihydroergotamine mesylate (DHE) to the upper nasal space.
Erenumab Bests Topiramate in Head-to-Head Migraine Prevention Study
The HER-MES study included 777 adult patients suffering from at least 4 migraine days/month and who were naïve to, not suitable for, or had previously failed up to 3 prophylactic treatments.
